Owlstone Medical Ltd is to receive an equity investment of up to $2.3 million from the US Cystic Fibrosis Foundation to develop a new breath test to detect a bacterial infection in patients with cystic fibrosis. The UK company has developed technology that can detect biological information from volatile organic compounds and respiratory droplets in breath. The newest project will involve developing a test for Pseudomonas aeruginosa, a Gram negative bacterial infection that can be particularly dangerous for people with compromised immune systems.
